Skip to main navigation Skip to search Skip to main content

Selective inhibition of the induction phase of delayed type hypersensitivity in mice by niridazole

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Niridazole, a nitrothiazole derivative, used in the treatment of schistosomiasis, inhibits cell-mediated immunity in mice. The drug depressed delayed type hypersensitivity (DTH)3 3 Abbreviations used: CMI, cell-mediated immunity; DTH, delayed type hypersensitivity; FGG, fowl gamma globulin; KLH, keyhole limpet haemocyanin; POL, polymerized bacteria flagellin; NIP, 4-hydroxy-3-iodo-5-nitrophenylacetic acid; PFC, plaque-forming cells. when administered at the time of sensitization, and lymph node cells from niridazole-treated mice were found to be less efficient than cells from untreated controls in transferring DTH, or in providing helper function in a plaque-forming cell assay. In contrast, the drug was unable to prevent passive sensitization when given to the recipient of sensitized cells. These studies suggest that niridazole inhibits cell-mediated immune responses primarily by interfering with the afferent arm of T-cell sensitization.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalClinical Immunology and Immunopathology
Volume20
Issue number3
DOIs
Publication statusPublished - 1981
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this